Format

Send to

Choose Destination
See comment in PubMed Commons below
J Heart Lung Transplant. 2009 Mar;28(3):280-4. doi: 10.1016/j.healun.2008.12.003.

Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.

Author information

1
Department of Pulmonology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.

Abstract

BACKGROUND:

The aim of our study was to describe the efficacy of addition of intravenous or subscutaneous prostanoids in idiopathic pulmonary arterial hypertension (PAH) patients deteriorating on bosentan or on bosentan-sildenafil.

METHODS:

PAH treatment at our hospital is standardized with first-line oral therapy in New York Heart Association class III patients followed by addition of prostanoids on clinical worsening.

RESULTS:

Mean improvement in 6-minute walk distance after 4 months of prostanoids was 86 m (p < 0.01) in the bosentan group versus 41 m (p < 0.05) in the bosentan-sildenafil group, and these improvements persisted at long-term follow-up.

CONCLUSIONS:

From these results we conclude that addition of subcutaneous or intravenous prostanoids can be efficacious in PAH deteriorating on oral therapy.

PMID:
19285621
DOI:
10.1016/j.healun.2008.12.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center